Navamedic ASA's fourth-quarter 2026 earnings call revealed a significant revenue miss. Actual revenue fell 14.35% short of forecasts. The company's stock dropped 8.33% during market hours.
Despite strong standalone profit growth, consolidated performance was impacted by deferred tax adjustments. Navamedic reported Q4 2026 revenue of $137.9 million, missing the $161 million forecast by 14.35%.
Following the announcement, the stock price fell 8.33% to $19.8 from $21.6. The stock has declined 13.55% over the past week and is trading near its 52-week low.
Management highlighted strong cash generation and liquidity, emphasizing the temporary nature of deferred tax liabilities. They expressed confidence in reversing these adjustments as exchange rates stabilize.
Analysts inquired about the impact of deferred tax adjustments and currency risk mitigation strategies. Executives reassured investors of their plans to manage these issues.
